Marksans Pharma Ltd. (MARKSANS): Marksans Pharma Share Price rises 5.49% to Rs 337.35

Published: 21 September 2026 at 12:49:04 PM IST

Marksans Pharma Share Price moved higher today, with the stock at Rs 337.35 after a 5.49% share price gain from the previous close of Rs 319.80. The company’s market capitalisation stands at Rs 14,492.18 Cr, placing the move in a large-company valuation context without assuming a company-specific trigger. On the supplied data, Marksans Pharma Stock News confirms the price event and the day’s range, but it does not establish a fresh catalyst.

The move matters because it comes alongside a day high of Rs 338.75, a low of Rs 323.20, and turnover of Rs 2.51 Cr. For readers tracking Marksans Pharma Share Price Today, the data shows a clear same-day advance in the Indian stock market, while the verified numbers also provide the starting point for Marksans Pharma Stock Analysis, Marksans Pharma Fundamental Analysis and broader market update coverage on Univest.

Marksans Pharma Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 337.35
Previous Close	Rs 319.8
Today's Move	Rs 17.55 (+5.49%)
Open	Rs 323.3
High	Rs 338.75
Low	Rs 323.2
Turnover	Rs 2.51 crore
Market Capitalisation	Rs 14,492.18 crore
Market Cap Category	Mid Cap

Marksans Pharma Ltd. (MARKSANS) rose to Rs 337.35 from the previous close of Rs 319.8, a move of Rs 17.55 or 5.49%. The stock opened at Rs 323.3, reached a high of Rs 338.75, recorded a low of Rs 323.2.

Marksans Pharma Share Price Today opened at Rs 323.30, touched a low of Rs 323.20 and moved to a high of Rs 338.75 before closing at Rs 337.35. That is a gain of Rs 17.55 over the previous close of Rs 319.80, or 5.49% on the day. The session data confirms a positive price rise, while the supplied numbers alone do not establish a company-specific reason for the move. For Marksans Pharma share price news readers, the important facts are the day’s range, the closing level and the market capitalisation of Rs 14,492.18 Cr. Univest tracks such stock updates through a factual price action lens rather than speculation.

Marksans Pharma Ltd. (MARKSANS) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 14,492.18 crore
P/E Ratio	28.05x
P/B Ratio	4.56x
ROE	15.31%
ROCE	21.1%
EPS	Rs 11.4
Book Value Per Share	Rs 70.16
Dividend Yield	0.28%

Marksans Pharma Ltd. (MARKSANS) fundamental metrics show P/E 28.05x, P/B 4.56x, ROE 15.31%, ROCE 21.1%. These figures provide context only and are not a buy or sell signal.

Marksans Pharma Ltd. has a market capitalisation of Rs 14492.18 crore and falls in the Mid Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 28.05x, P/B at 4.56x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 15.31% and ROCE of 21.1%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 11.4, book value per share of Rs 70.16, dividend yield of 0.28%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 32.87x, median ROE of 11.7%, median ROCE of 13.46%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	28.05x
Benchmark Median P/E	32.87x
Benchmark Average P/E	48.77x
Benchmark P/E Range	3.4x to 683.5x
Company P/B Ratio	4.56x
Benchmark Median P/B	3.08x
Company ROE	15.31%
Benchmark Median ROE	11.7%
Company ROCE	21.1%
Benchmark Median ROCE	13.46%
Company Market Capitalisation	Rs 14,492.18 crore
Benchmark Median Market Cap	Rs 701.78 crore

Marksans Pharma Ltd. (MARKSANS) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Marksans Pharma Ltd. (MARKSANS) has a P/E ratio of 28.05x, which is below the benchmark median of 32.87x, a difference of -14.66%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Marksans Pharma Ltd. (MARKSANS) has a ROE of 15.31%, which is above the benchmark median of 11.7%, a difference of +30.85%. Marksans Pharma Ltd. (MARKSANS) has a ROCE of 21.1%, which is above the benchmark median of 13.46%, a difference of +56.76%.

Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries Ltd.	SUNPHARMA	4,40,397.93	36.41	5.09	14.85	19.11
Divi's Laboratories Ltd.	DIVISLAB	2,48,664.42	85.01	14.08	16.19	21.51
Torrent Pharmaceuticals Ltd.	TORNTPHARM	1,82,738.23	83.79	20.36	26.76	19.27
Zydus Lifesciences Ltd.	ZYDUSLIFE	1,15,012.19	25.48	4.27	19.69	21.39
Cipla Ltd.	CIPLA	1,10,793.75	32.87	3.15	11.83	16

Marksans Pharma Ltd. (MARKSANS) has a P/E ratio of 28.05x compared with the displayed peer median of 36.41x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 15.31% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 21.1% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Marksans Pharma Ltd. (MARKSANS) has a market capitalisation of Rs 14,492.18 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Why Investors Are Watching Marksans Pharma

• Marksans Pharma Share Price rose 5.49% today to Rs 337.35 after closing above the previous close of Rs 319.80.
• The day’s high of Rs 338.75 and low of Rs 323.20 define the observed price action in Marksans Pharma Share Price Today.
• Market capitalisation stands at Rs 14,492.18 Cr, which is far above the same-industry median of Rs 701.78 Cr.
• P/E is 28.05, while ROE is 15.31 and ROCE is 21.1, giving Marksans Pharma Fundamental Analysis a clear valuation and profitability reference.
• EPS is 11.4, book value is 70.16 and dividend yield is 0.28, which are relevant in Marksans Pharma Stock Analysis and Marksans Pharma Share Price news.

About Marksans Pharma

Marksans Pharma Ltd. is part of the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied data identifies the company through its NSE symbol MARKSANS and shows it as a listed Indian pharmaceutical business tracked by Univest. The article data does not provide a segment-by-segment revenue mix or product list, so the company overview here remains strictly tied to verified market and financial fields.

From the available figures, the company’s market capitalisation, profitability ratios, earnings per share, book value and dividend yield create the core of its public market profile. That is why Marksans Pharma Stock News today is best understood through both the day’s share price rise and the financial context behind it. For readers scanning Marksans Pharma Latest News or Marksans Pharma Company News, the key point is that the supplied data confirms a listed healthcare business with measurable valuation and profitability metrics.

Track Marksans Pharma Share Price on Univest

Use Marksans Pharma Ltd. (MARKSANS) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.

Frequently Asked Questions

Why did Marksans Pharma Share Price rise today?

Ans. The supplied data confirms a 5.49% same-day rise to Rs 337.35, but it does not establish a company-specific catalyst. The verified facts are the price move, day range, turnover and market capitalisation.

What is Marksans Pharma Share Price Today?

Ans. Marksans Pharma Share Price Today is Rs 337.35. It rose Rs 17.55 from the previous close of Rs 319.80 and traded between Rs 323.20 and Rs 338.75 during the session.

What is the market capitalisation of Marksans Pharma?

Ans. Marksans Pharma has a market capitalisation of Rs 14,492.18 Cr. That is well above the same-industry median of Rs 701.78 Cr and slightly above the benchmark average of Rs 13,926.75 Cr.

How does Marksans Pharma look on valuation?

Ans. Marksans Pharma’s P/E ratio is 28.05 and P/B ratio is 4.56. The P/E is below the same-industry median of 32.87, while P/B is above the median of 3.08. The company trades at a P/E ratio of 28.05x.

What do the profitability ratios show for Marksans Pharma?

Ans. ROE is 15.31 and ROCE is 21.1. Both are above the same-industry medians and averages in the supplied benchmark, which gives the Marksans Pharma Share Price additional financial context. ROE stands at 15.31%.

How do EPS, book value and dividend yield read for Marksans Pharma?

Ans. EPS is 11.4, book value is 70.16 and dividend yield is 0.28. EPS shows earnings per share, book value shows accounting net worth per share and dividend yield shows the current payout context.

How does Marksans Pharma compare with sector peers?

Ans. Compared with Sun Pharma, Divi's, Torrent, Zydus and Cipla, Marksans Pharma sits in a middle valuation zone. Its profitability ratios are stronger than some peers and below others, based on the supplied numbers.